OptimizeRx (OPRX) Long-Term Deferred Tax (2013 - 2024)

OptimizeRx (OPRX) has 9 years of Long-Term Deferred Tax data on file, last reported at $4.5 million in Q4 2024.

• For the quarter ending Q4 2024, Long-Term Deferred Tax rose 3.55% year-over-year to $4.5 million; the trailing twelve-month figure through Dec 2024 stood at $4.5 million (up 3.55% YoY), and the FY2024 full-year result was $4.5 million, up 3.55% from the prior year.
• Long-Term Deferred Tax grew to $4.5 million in Q4 2024, from $4.3 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $10.5 million in Q4 2022 to a low of $300000.0 in Q3 2023.
• A 5-year average of $5.3 million and a median of $4.5 million in 2020 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax jumped 73.31% in 2021 and sank 58.66% in 2023, its largest moves.
• Tracing OPRX's Long-Term Deferred Tax over 5 years: stood at $4.5 million in 2020, then jumped by 73.31% to $7.9 million in 2021, then surged by 33.11% to $10.5 million in 2022, then slumped by 58.66% to $4.3 million in 2023, then increased by 3.55% to $4.5 million in 2024.
• Business Quant data shows OPRX's Long-Term Deferred Tax at $4.5 million in Q4 2024, $4.3 million in Q4 2023, and $300000.0 in Q3 2023.